Lipid patterns in treated growth hormone deficient children vs. short stature controls
-
Christy Foster
Abstract
Context: Previous studies in adults with growth hormone (GH) deficiency have substantiated an increased risk of cardiovascular events. This risk has been attributed to an unpropitious lipid profile, increased abdominal mass, and higher incidence of metabolic syndrome. In these studies, a collateral observation has been a negative correlation between IGF-1 levels and lipid profiles. Longitudinal studies are lacking in children with GH-deficiency wherein the various lipid subfractions after GH treatment were compared to matched GH-sufficient short stature controls. Our study examined changes in small lipid particles following GH treatment.
Objective: The primary objective was to determine the effect of GH treatment on serum lipids in GH-deficient patients vs. short controls.
Design, setting, and participants: This was a prospective, unblinded, case-controlled, 6-month trial conducted at a tertiary pediatric referral center. Patients were referred for short stature. Incorporating accepted criteria, the treatment group (n=18) was found to be GH-deficient, whereas the control group (n=13) was GH-sufficient. The two groups had near-identical short stature along in addition to baseline measurements of weight and BMI.
Interventions: The treatment arm received 6 months of recombinant GH at standard doses.
Main outcome measures: The primary endpoint was the comparison of the lipoprotein subclasses and lipids between the two groups after 6 months.
Results: With the exception of the intermediate density lipoprotein (IDL), there were no significant differences at baseline in serum lipid profiles between the GH-deficient children and the controls. After 6 months of therapy, there were statistically significant differences in Apo-B, LDL, and smaller lipoparticles (LDL-3 and non-HDL) in GH-treated children compared to untreated GH-sufficient short children.
Conclusions: Our findings indicate that GH replacement may improve cardiovascular outcome by favorably altering lipid profiles.
Acknowledgments
The study was funded by an Investigator Initiated Trial grant from Novo Nordisk Inc. The sponsor was not involved in the study design, the data collection or interpretation, the manuscript composition, or publishing decisions.
Conflict of interest statement
Funding source: Novo Nordisk.
References
1. Abdu TA, Neary R, Elhadd TA, Akber M, Clayton RN. Coronary risk in growth hormone deficient hypopituitary adults: increased predicted risk is due largely to lipid profile abnormalities. Clin Endocrinol (Oxf) 2001;55:209–16.10.1046/j.1365-2265.2001.01320.xSuche in Google Scholar
2. Carroll PV, Christ ER, Bengtsson BA, Carlsson L, Christiansen JS. et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab 1998;83:382–95.10.1210/jcem.83.2.4594Suche in Google Scholar
3. Colao A, Di Somma C, Savanelli MC, De Leo M, Lombardi G. Beginning to end: cardiovascular implications of growth hormone (GH) deficiency and GH therapy. Growth Horm IGF Res 2006;16 Suppl A:S41–8.10.1016/j.ghir.2006.03.006Suche in Google Scholar
4. Di Somma C, Pivonello R, Pizza G, De Rosa A, Lombardi G, et al. Prevalence of the metabolic syndrome in moderately-severely obese subjects with and without growth hormone deficiency. J Endocrinol Invest 2010;33:171–7.10.1007/BF03346577Suche in Google Scholar
5. Utz AL, Yamamoto A, Hemphill L, Miller KK. Growth hormone deficiency by growth hormone releasing hormone-arginine testing criteria predicts increased cardiovascular risk markers in normal young overweight and obese women. J Clin Endocrinol Metab 2008;93:2507–14.10.1210/jc.2008-0169Suche in Google Scholar
6. Arai Y, Kojima T, Takayama M, Hirose N. The metabolic syndrome, IGF-1, and insulin action. Mol Cell Endocrinol 2009;299:124–8.10.1016/j.mce.2008.07.002Suche in Google Scholar
7. de Boer H, Blok GJ, Voerman HJ, Phillips M, Schouten JA. Serum lipid levels in growth hormone-deficient men. Metabolism 1994;43:199–203.10.1016/0026-0495(94)90245-3Suche in Google Scholar
8. Vahl N, Klausen I, Christiansen JS, Jorgensen JO. Growth hormone (GH) status is an independent determinant of serum levels of cholesterol and triglycerides in healthy adults. Clin Endocrinol (Oxf) 1999;51:309–16.10.1046/j.1365-2265.1999.00772.xSuche in Google Scholar PubMed
9. Imrie H, Abbas A, Viswambharan H, Rajwani A, Cubbon RM, et al. Vascular insulin-like growth factor-I resistance and diet-induced obesity. Endocrinology 2009;150:4575–82.10.1210/en.2008-1641Suche in Google Scholar PubMed
10. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 2002;106:939–44.10.1161/01.CIR.0000027563.44593.CCSuche in Google Scholar PubMed
11. Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab 2004;89:114–120.10.1210/jc.2003-030967Suche in Google Scholar PubMed
12. De Boer H, Blok GJ, Voerman HJ, De Vries PM, van der Veen EA. Body composition in adult growth hormone-deficient men, assessed by anthropometry and bioimpedance analysis. J Clin Endocrinol Metab 1992;75:833–837.Suche in Google Scholar
13. Makimura H, Feldpausch MN, Stanley TL, Sun N, Grinspoon SK. Reduced growth hormone secretion in obesity is associated with smaller LDL and HDL particle size. Clin Endocrinol (Oxf) 2012;76:220–7.10.1111/j.1365-2265.2011.04195.xSuche in Google Scholar PubMed PubMed Central
14. Johansson J, Carlson LA, Landou C, Hamsten A. High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler Thromb 1991;11:174–82.10.1161/01.ATV.11.1.174Suche in Google Scholar
15. O’Brien T, Nguyen TT, Hallaway BJ, Hodge D, Bailey K, et al. The role of lipoprotein A-I and lipoprotein A-I/A-II in predicting coronary artery disease. Arterioscler Thromb Vasc Biol 1995;15:228–31.10.1161/01.ATV.15.2.228Suche in Google Scholar
16. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997; 95:69–75.10.1161/01.CIR.95.1.69Suche in Google Scholar
17. Cziraky MJ, Watson KE, Talbert RL. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag Care Pharm 2008;14:S328; quiz S30–21.10.18553/jmcp.2008.14.S8-A.1Suche in Google Scholar PubMed
18. Rudling M, Angelin B. Growth hormone reduces plasma cholesterol in LDL receptor-deficient mice. FASEB J 2001;15:1350–6.10.1096/fj.00-0715comSuche in Google Scholar PubMed
19. Sukhanov S, Higashi Y, Shai SY, Vaughn C, Mohler J, et al. IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2007;27:2684–90.10.1161/ATVBAHA.107.156257Suche in Google Scholar PubMed
20. Deepak D, Daousi C, Javadpour M, Clark D, Perry Y, et al. The influence of growth hormone replacement on peripheral inflammatory and cardiovascular risk markers in adults with severe growth hormone deficiency. Growth Horm IGF Res 2010;20:220–5.10.1016/j.ghir.2010.02.002Suche in Google Scholar PubMed
21. Schneider HJ, Klotsche J, Wittchen HU, Stalla GK, Schopohl J, et al. Effects of growth hormone replacement within the KIMS survey on estimated cardiovascular risk and predictors of risk reduction in patients with growth hormone deficiency. Clin Endocrinol (Oxf) 2011;75:825–30.10.1111/j.1365-2265.2011.04137.xSuche in Google Scholar PubMed
22. Jallad RS, Liberman B, Vianna CB, Vieira ML, Ramires JA, et al. Effects of growth hormone replacement therapy on metabolic and cardiac parameters, in adult patients with childhood-onset growth hormone deficiency. Growth Horm IGF Res 2003;13:81–8.10.1016/S1096-6374(03)00006-6Suche in Google Scholar
23. Boguszewski CL, Meister LH, Zaninelli DC, Radominski RB. One year of GH replacement therapy with a fixed low-dose regimen improves body composition, bone mineral density and lipid profile of GH-deficient adults. Eur J Endocrinol 2005;152:67–75.10.1530/eje.1.01817Suche in Google Scholar PubMed
24. Claessen KM, Appelman-Dijkstra NM, Adoptie DM, Roelfsema F, Smit JW, et al. Metabolic profile in growth hormone-deficient (GHD) adults after long-term recombinant human growth hormone (rhGH) therapy. J Clin Endocrinol Metab 2013;98:352–61.10.1210/jc.2012-2940Suche in Google Scholar PubMed
25. Elbornsson M, Gotherstrom G, Bosaeus I, Bengtsson BA, Johannsson G, et al. Fifteen years of GH replacement improves body composition and cardiovascular risk factors. Eur J Endocrinol 2013;168:745–53.10.1530/EJE-12-1083Suche in Google Scholar PubMed PubMed Central
26. Christ ER, Chowienczyk PJ, Sonksen PH, Russel-Jones DL. Growth hormone replacement therapy in adults with growth hormone deficiency improves vascular reactivity. Clin Endocrinol (Oxf) 1999;51:21–5.10.1046/j.1365-2265.1999.00805.xSuche in Google Scholar PubMed
27. Salerno M, Esposito V, Spinelli L, Di Somma C, Farina V, et al. Left ventricular mass and function in children with GH deficiency before and during 12 months GH replacement therapy. Clin Endocrinol (Oxf) 2004;60:630–6.10.1111/j.1365-2265.2004.02026.xSuche in Google Scholar PubMed
28. Johannsson G, Albertsson-Wikland K, Bengtsson BA. Discontinuation of growth hormone (GH) treatment: metabolic effects in GH-deficient and GH-sufficient adolescent patients compared with control subjects. Swedish Study Group for Growth Hormone Treatment in Children. J Clin Endocrinol Metab 1999; 84:4516–24.Suche in Google Scholar
29. Gleeson H, Barreto ES, Salvatori R, Costa L, Oliveira CR, et al. Metabolic effects of growth hormone (GH) replacement in children and adolescents with severe isolated GH deficiency due to a GHRH receptor mutation. Clin Endocrinol (Oxf) 2007;66:466–74.10.1111/j.1365-2265.2007.02753.xSuche in Google Scholar PubMed
30. Kulkarni KR. Cholesterol profile measurement by vertical auto profile method. Clin Lab Med 2006;26:787–802.10.1016/j.cll.2006.07.004Suche in Google Scholar PubMed
31. Hodis HN, Mack WJ, Dunn M, Liu C, Liu C, et al. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation 1997; 95:2022–6.10.1161/01.CIR.95.8.2022Suche in Google Scholar PubMed
32. Ciresi A, Amato MC, Criscimanna A, Mattina A, Vetro C, et al. Metabolic parameters and adipokine profile during GH replacement in children with GH deficiency. Eur J Endocrinol 2007;156:353–360.10.1530/eje.1.02343Suche in Google Scholar PubMed
33. Sniderman AD, Jungner I, Holme I, Aastveit A, Walldius G. Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease. J Intern Med 2006;259:455–61.10.1111/j.1365-2796.2006.01649.xSuche in Google Scholar PubMed
34. Filipsson Nystrom H, Barbosa EJ, Nilsson AG, Norrman LL, Ragnarsson O, et al. Discontinuing long-term GH replacement therapy--a randomized, placebo-controlled crossover trial in adult GH deficiency. J Clin Endocrinol Metab 2012;97:3185–95.10.1210/jc.2012-2006Suche in Google Scholar PubMed
35. Daniels SR, Greer FR. Lipid screening and cardiovascular health in childhood. Pediatrics 2008;122:198–208.10.1542/peds.2008-1349Suche in Google Scholar PubMed
©2014 by De Gruyter
Artikel in diesem Heft
- Frontmatter
- Review article
- Towards an optimization of the management of endocrine complications of thalassemia
- Original articles
- The natural course of Hashimoto’s thyroiditis in children and adolescents
- Muscle strength and body composition during the transition phase in patients treated with recombinant GH to final height
- Benign vaginal bleeding in 24 prepubertal patients: clinical, biochemical and imaging features
- Evaluation of epicardial adipose tissue, carotid intima-media thickness and ventricular functions in obese children and adolescents
- Counseling patients with succinate dehydrogenase subunit defects: genetics, preventive guidelines, and dealing with uncertainty
- Pubertal development profile in patients with Turner syndrome
- A novel CASR mutation associated with neonatal severe hyperparathyroidism transmitted as an autosomal recessive disorder
- Serum insulin-like growth factor-binding protein-3 level correlated with glycemic control and lipid profiles in children and adolescents with type 1 diabetes
- Adult human liver mesenchymal progenitor cells express phenylalanine hydroxylase
- Clinical applicability of rapid detection of SRY and DYS14 genes in patients with disorders of sex development using an indigenously developed 5′ exonuclease based assay
- Hereditary 1,25-dihydroxyvitamin D-resistant rickets with alopecia in four Egyptian families: report of three novel mutations in the vitamin D receptor gene
- Permanent neonatal diabetes mellitus in Jordan
- The effect of adenotonsilectomy on ghrelin, leptin, IGF-1 levels and growth parameters in children with adenotonsillar hypertrophy
- The role of anti-Mullerian and inhibin B hormones in the evaluation of 46,XY disorders of sex development
- The evaluation of thyroid carcinoma in childhood and concomitance of autoimmune thyroid disorders
- Lipid patterns in treated growth hormone deficient children vs. short stature controls
- Assessment of aortic morphology and compliance in children and adolescents with Ullrich-Turner syndrome (UTS) using magnetic resonance imaging (MRI)
- Management of central diabetes insipidus with oral desmopressin lyophilisate in infants
- Maternal factors and complications of preterm birth associated with neonatal thyroid stimulating hormone
- Patient reports
- A rare case of pituitary infarction leading to spontaneous tumour resolution and CSF-sella syndrome in an 11-year-old girl and a review of the paediatric literature
- Rare case of homozygous epimerase deficiency and heterozygous of duarte 2 variant
- Persistent congenital hyperinsulinism in two patients with Beckwith-Wiedemann syndrome due to mosaic uniparental disomy 11p
- Growth hormone treatment in a patient with Hurler-Scheie syndrome
- Neonatal diagnosis of a patient with hypoparathyroidism, sensorineural deafness and renal dysplasia (HDR) syndrome associated with cerebral infarction
- Early-onset diabetes mellitus and neurodevelopmental retardation: the first Greek case of Wolcott-Rallison syndrome
- Type III Bartter-like syndrome in an infant boy with Gitelman syndrome and autosomal dominant familial neurohypophyseal diabetes insipidus
- Cushing’s syndrome: hidden risk in usage of topical corticosteroids
- Prader-Willi syndrome: a case report with atypical developmental features
- Berardinelli-Seip congenital lipodystrophy: an autosomal recessive disorder with rare association of duodenocolonic polyps
- Ectopic Cushing syndrome secondary to metastatic medullary thyroid cancer in a child with multiple endocrine neoplasia syndrome type 2B: clues to early diagnosis of the paraneoplastic syndromes
- Ovarian hyperstimulation syndrome treated by medroxyprogesterone acetate
- Symptomatic cerebral infarction in a child with severe diabetic ketoacidosis
- A rare case of familial Cushing’s syndrome with a common presentation of weight gain due to a mutation of the PRKAR1A gene causing isolated primary pigmented nodular adrenocortical disease
- Multiple autoimmunity, type 1 diabetes (T1DM), autoimmune thyroiditis and thyroid cancer: is there an association? A case report and literature review
- Cholestasis and protein-losing enteropathy secondary to hyperthyroidism in a 6-year-old girl
- Short communication
- An essential splice site mutation (c.317+1G>A) in the TSHR gene leads to severe thyroid dysgenesis
- Letter to the Editor
- Pubertal gynecomastia: what about the remaining 10%?
Artikel in diesem Heft
- Frontmatter
- Review article
- Towards an optimization of the management of endocrine complications of thalassemia
- Original articles
- The natural course of Hashimoto’s thyroiditis in children and adolescents
- Muscle strength and body composition during the transition phase in patients treated with recombinant GH to final height
- Benign vaginal bleeding in 24 prepubertal patients: clinical, biochemical and imaging features
- Evaluation of epicardial adipose tissue, carotid intima-media thickness and ventricular functions in obese children and adolescents
- Counseling patients with succinate dehydrogenase subunit defects: genetics, preventive guidelines, and dealing with uncertainty
- Pubertal development profile in patients with Turner syndrome
- A novel CASR mutation associated with neonatal severe hyperparathyroidism transmitted as an autosomal recessive disorder
- Serum insulin-like growth factor-binding protein-3 level correlated with glycemic control and lipid profiles in children and adolescents with type 1 diabetes
- Adult human liver mesenchymal progenitor cells express phenylalanine hydroxylase
- Clinical applicability of rapid detection of SRY and DYS14 genes in patients with disorders of sex development using an indigenously developed 5′ exonuclease based assay
- Hereditary 1,25-dihydroxyvitamin D-resistant rickets with alopecia in four Egyptian families: report of three novel mutations in the vitamin D receptor gene
- Permanent neonatal diabetes mellitus in Jordan
- The effect of adenotonsilectomy on ghrelin, leptin, IGF-1 levels and growth parameters in children with adenotonsillar hypertrophy
- The role of anti-Mullerian and inhibin B hormones in the evaluation of 46,XY disorders of sex development
- The evaluation of thyroid carcinoma in childhood and concomitance of autoimmune thyroid disorders
- Lipid patterns in treated growth hormone deficient children vs. short stature controls
- Assessment of aortic morphology and compliance in children and adolescents with Ullrich-Turner syndrome (UTS) using magnetic resonance imaging (MRI)
- Management of central diabetes insipidus with oral desmopressin lyophilisate in infants
- Maternal factors and complications of preterm birth associated with neonatal thyroid stimulating hormone
- Patient reports
- A rare case of pituitary infarction leading to spontaneous tumour resolution and CSF-sella syndrome in an 11-year-old girl and a review of the paediatric literature
- Rare case of homozygous epimerase deficiency and heterozygous of duarte 2 variant
- Persistent congenital hyperinsulinism in two patients with Beckwith-Wiedemann syndrome due to mosaic uniparental disomy 11p
- Growth hormone treatment in a patient with Hurler-Scheie syndrome
- Neonatal diagnosis of a patient with hypoparathyroidism, sensorineural deafness and renal dysplasia (HDR) syndrome associated with cerebral infarction
- Early-onset diabetes mellitus and neurodevelopmental retardation: the first Greek case of Wolcott-Rallison syndrome
- Type III Bartter-like syndrome in an infant boy with Gitelman syndrome and autosomal dominant familial neurohypophyseal diabetes insipidus
- Cushing’s syndrome: hidden risk in usage of topical corticosteroids
- Prader-Willi syndrome: a case report with atypical developmental features
- Berardinelli-Seip congenital lipodystrophy: an autosomal recessive disorder with rare association of duodenocolonic polyps
- Ectopic Cushing syndrome secondary to metastatic medullary thyroid cancer in a child with multiple endocrine neoplasia syndrome type 2B: clues to early diagnosis of the paraneoplastic syndromes
- Ovarian hyperstimulation syndrome treated by medroxyprogesterone acetate
- Symptomatic cerebral infarction in a child with severe diabetic ketoacidosis
- A rare case of familial Cushing’s syndrome with a common presentation of weight gain due to a mutation of the PRKAR1A gene causing isolated primary pigmented nodular adrenocortical disease
- Multiple autoimmunity, type 1 diabetes (T1DM), autoimmune thyroiditis and thyroid cancer: is there an association? A case report and literature review
- Cholestasis and protein-losing enteropathy secondary to hyperthyroidism in a 6-year-old girl
- Short communication
- An essential splice site mutation (c.317+1G>A) in the TSHR gene leads to severe thyroid dysgenesis
- Letter to the Editor
- Pubertal gynecomastia: what about the remaining 10%?
